Skip to content
DataLookout
Menu

NCT07813572

ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Recruitment opened
    • Start date changed from estimate of Sep 2026 to Oct 20, 2026
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Progression-free survival (PFS)
Timeframe: up to 3 years
Overall survival (OS)
Timeframe: up to 5 years

Secondary (2)

PFS
Objective response rate (ORR)

Arms and interventions

ZG005+BevacizumabExperimental

ZG005 20 mg/kg administered intravenously every 3 weeks (Q3W) + Bevacizumab(Avastin) 15 mg/kg administered intravenously Q3W

Sintilimab Plus BevacizumabActive comparator

Sintilimab 200 mg administered intravenously Q3W + Bevacizumab (达攸同) 15 mg/kg administered intravenouslyQ3W

Drugs: ZG005 for Injection, Bevacizumab ( Avastin), Sintilimab, Bevacizumab

Sites

1 site in 1 country

  • Nanjing Tianyinshan HospitalNanjing, Jiangsu, China